Search

Your search keyword '"Krex, Dietmar"' showing total 346 results
Start Over Author "Krex, Dietmar" Publication Year Range Last 10 years
346 results on '"Krex, Dietmar"'

4. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D’Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Brain Disorders, Brain Cancer, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Humans, Glioblastoma, Temozolomide, Prospective Studies, Brain Neoplasms, Recurrence, Dendritic Cells, Vaccination, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P

Published
2023

5. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Author

Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich, and Schaub, Christina

Published
2023
Full Text
View/download PDF

6. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up

Author

Pertz, Milena, Schlömer, Sabine, Seidel, Clemens, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Wick, Antje, Fliessbach, Klaus, Hoppe, Christian, Klingner, Marcel, Felsberg, Jörg, Reifenberger, Guido, Gramatzki, Dorothee, Weller, Michael, and Schlegel, Uwe

Published
2023
Full Text
View/download PDF

7. INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Author

Grassl, Niklas, Sahm, Katharina, Süße, Heike, Poschke, Isabel, Bunse, Lukas, Bunse, Theresa, Boschert, Tamara, Mildenberger, Iris, Rupp, Anne-Kathleen, Ewinger, Max Philipp, Lanz, Lisa-Marie, Denk, Monika, Tabatabai, Ghazaleh, Ronellenfitsch, Michael W., Herrlinger, Ulrich, Glas, Martin, Krex, Dietmar, Vajkoczy, Peter, Wick, Antje, Harting, Inga, Sahm, Felix, von Deimling, Andreas, Bendszus, Martin, Wick, Wolfgang, and Platten, Michael

Published
2023
Full Text
View/download PDF

8. Expertise in surgical neuro-oncology. Results of a survey by the EANS neuro-oncology section

Author

Agrawal, Rachit, Albano, Luigi, Alexiou, George A., Ali, Amanj, Al-Mahfoudh, Rafid, Amoo, Michael, Anagnostopoulos, Christos, Bamps, Sven, Bandyopadhyay, Soham, Barone, Damiano G., Barone, Fabio, Barrit, Sami, Behling, Felix, Blaga, Alin, Boukas, Alexandros, Brennan, Paul, Butenschoen, Vicki M., Campello, Mauro, Cara, Areda, Chibbaro, Salvatore, Chrenko, Robert, Cifre Serra, Pere J., Clusmann, Hans, Corell, Alba, Cornelius, Jan F., D'Andrea, Marcello, Demetriades, Andreas K., De Vleeschouwer, Steven, Drexler, Richard, Duerinck, Johnny, Fanarjyan, Ruben V., Fernandez-Coello, Alejandro, Fountas, Kostas, Freiman, Thomas M., Gadzhiagaev, Vadim, Georgiopoulos, Miltiadis, Gilis, Nathalie, Golubovic, Jagos, Lippi Fernandes, Eric Goulin, Grasso, Giovanni, Guerrini, Francesco, Gulsuna, Beste, Hill, Ciaran S., Höhne, Julius, Holling, Markus, Iarmoliuk, Ievgenii, Ioan-Alexandru, Florian, Ius, Tamara, Jacikevicius, Kestutis, Jakola, Asgeir S., Jakubowski, Paweł, Kalantzis, Georgios, Karabatsou, Konstantina, Kirollos, Ramez, König, Ralph, Kozyrev, Danil A., Krex, Dietmar, Ladisich, Barbara, Lau, Ruth, Lizunou, Yauhen, Lombard, Arnaud, Low, Hu Liang, Alves, José Luís, Maghrabi, Yazid, Mammi, Marco, Marji, Ala, Massimi, Luca, Mavridis, Ioannis, McLean, Aaron Lawson, Lawson McLean, Anna C., Meyer, Bernhard, Mohme, Malte, Branco, Pedro Moura, Müther, Michael, Musleh, Issam, Nasiri, Danial, Navarro, Ramon, Omerhodzic, Ibrahim, Oppong, Marvin Darkwah, Paidakakos, Nikolaos A., Pantera, Zoi, Patel, Mohammed A., Pawlowski, Mateusz, Petridis, Athanasios, Praeger, Adrian J., Price, Stephen, Ricklefs, Franz, Rigante, Luigi, Ringel, Florian, Robe, Pierre A., Rössler, Karl, Sá-Marta, Eduarda, Sanmillan, Jose L., Scerrati, Alba, Schneider, Matthias, Schroeder, Henry W.S., Schwake, Michael, Shoaib, Mohamed, Sirbu, Octavian Mihai, Sistiaga, Iñigo L., Skajster, Tomasz J., Sliauzys, Albertas, Sokotukhin, Vitaly, Soleman, Jehuda, Stoecklein, Veit M., Suero Molina, Eric, Świątnicki, Wojciech, Syrmos, Νikolaos, Taddei, Graziano, Taher, Avin, Tamarit, Martin, Laan, Mark ter, Theocharous, Theocharis, Thijs, Dieter, Trakolis, Leonidas, Truffelli, Monica, Weiss, Miriam, Uhl, Eberhard, Valentini, Laura Grazia, Vanhauwaert, Dimitri, Zebian, Bassel, Zivkovic, Bojana, Zoli, Matteo, Gousias, K., Hoyer, A., Mazurczyk, L.A., Bartek, J., Jr., Bruneau, M., Celtikci, E., Foroglou, N., Freyschlag, C., Grossman, R., Jungk, C., Metellus, P., Netuka, D., Rola, R., Schucht, P., Senft, C., Signorelli, F., Vincent, A.J.P.E., and Simon, M.

Published
2024
Full Text
View/download PDF

9. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Author

Hertler, Caroline, Felsberg, Jörg, Gramatzki, Dorothee, Le Rhun, Emilie, Clarke, Jennifer, Soffietti, Riccardo, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F., Reijneveld, Jaap, Schnell, Oliver, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A., van den Bent, Martin, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F., Phillips, Samuel, Rudà, Roberta, Wick, Antje, Tabouret, Emeline, Meyronet, David, Maurage, Claude-Alain, Rushing, Elisabeth, Rapkins, Robert, Bumes, Elisabeth, Hegi, Monika, Weyerbrock, Astrid, Aregawi, Dawit, Gonzalez-Gomez, Christian, Pellerino, Alessia, Klein, Martin, Preusser, Matthias, Bendszus, Martin, Golfinopoulos, Vassilis, von Deimling, Andreas, Gorlia, Thierry, Wen, Patrick Y., Reifenberger, Guido, and Weller, Michael

Published
2023
Full Text
View/download PDF

10. Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

Author

Zeyen, Thomas, Paech, Daniel, Weller, Johannes, Schäfer, Niklas, Tzaridis, Theophilos, Duffy, Cathrina, Nitsch, Louisa, Schneider, Matthias, Potthoff, Anna-Laura, Steinbach, Joachim Peter, Hau, Peter, Schlegel, Uwe, Seidel, Clemens, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Zeiner, Pia Susan, Tabatabai, Ghazaleh, Galldiks, Norbert, Stummer, Walter, Hattingen, Elke, Glas, Martin, Radbruch, Alexander, Herrlinger, Ulrich, and Schaub, Christina

Published
2023
Full Text
View/download PDF

11. Mid-term treatment-related cognitive sequelae in glioma patients

Author

Schlömer, Sabine, Felsberg, Jörg, Pertz, Milena, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Fliessbach, Klaus, Hoppe, Christian, Reifenberger, Guido, Weller, Michael, Schlegel, Uwe, and Network, for the German Glioma

Published
2022
Full Text
View/download PDF

12. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS

Author

Weller, Johannes, Schäfer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Güresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich, and Schneider, Matthias

Published
2022
Full Text
View/download PDF

13. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Brain Cancer, Neurosciences, Immunization, Clinical Research, Cancer, Brain Disorders, Rare Diseases, Patient Safety, Prevention, Vaccine Related, Orphan Drug, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Brain Neoplasms, Cancer Vaccines, Dendritic Cells, Endpoint Determination, Female, Glioblastoma, Humans, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Young Adult, Immunotherapy, Dendritic cell, Vaccine, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundStandard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma.MethodsAfter surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS).ResultsFor the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone.ConclusionsAddition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival. Trial registration Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&rank=1 ; initially registered 19 September 2002.

Published
2018

14. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Neurosciences, Brain Disorders, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

Published
2018

15. Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial

Author

Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Güresir, Erdem, Schmid, Matthias, Schuss, Patrick, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank, Herrlinger, Ulrich, and Schneider, Matthias

Published
2022
Full Text
View/download PDF

16. Expertise in Surgical Neuro-oncology. Results of a Survey by the EANS Neuro-oncology Section.

Author

Gousias, K., primary, Hoyer, A., additional, Mazurczyk, L.A., additional, Bartek, J., additional, Bruneau, M., additional, Celtikci, E., additional, Foroglou, N., additional, Freyschlag, C., additional, Grossman, R., additional, Jungk, C., additional, Metellus, P., additional, Netuka, D., additional, Rola, R., additional, Schucht, P., additional, Senft, C., additional, Signorelli, F., additional, Vincent, A.J.P.E., additional, Simon, M., additional, Agrawal, Rachit, additional, Albano, Luigi, additional, Alexiou, George A., additional, Ali, Amanj, additional, Al-Mahfoudh, Rafid, additional, Amoo, Michael, additional, Anagnostopoulos, Christos, additional, Bamps, Sven, additional, Bandyopadhyay, Soham, additional, Barone, Damiano G., additional, Barone, Fabio, additional, Barrit, Sami, additional, Behling, Felix, additional, Blaga, Alin, additional, Boukas, Alexandros, additional, Brennan, Paul, additional, Butenschoen, Vicki M., additional, Campello, Mauro, additional, Cara, Areda, additional, Chibbaro, Salvatore, additional, Chrenkol, Robert, additional, Cifre Serra, Pere J., additional, Clusmann, Hans, additional, Corell, Alba, additional, Cornelius, Jan F., additional, D'Andrea, Marcello, additional, Demetriades, Andreas K., additional, De Vleeschouwer, Steven, additional, Drexler, Richard, additional, Duerinck, Johnny, additional, Fanarjyan, Ruben V., additional, Fernandez-Coello, Alejandro, additional, Fountas, Kostas, additional, Freiman, Thomas M., additional, Gadzhiagaev, Vadim, additional, Georgiopoulos, Miltiadis, additional, Gilis, Nathalie, additional, Golubovic, Jagos, additional, Lippi Fernandes, Eric Goulin, additional, Grasso, Giovanni, additional, Guerrini, Francesco, additional, Gulsuna, Beste, additional, Hill, Ciaran S., additional, Höhne, Julius, additional, Holling, Markus, additional, Iarmoliuk, Ievgenii, additional, Ioan-Alexandru, Florian, additional, Ius, Tamara, additional, Jacikevicius, Kestutis, additional, Jakola, Asgeir S., additional, Jakubowski, Paweł, additional, Kalantzis, Georgios, additional, Karabatsou, Konstantina, additional, Kirollos, Ramez, additional, König, Ralph, additional, Kozyrev, Danil A., additional, Krex, Dietmar, additional, Ladisich, Barbara, additional, Lau, Ruth, additional, Lizunou, Yauhen, additional, Lombard, Arnaud, additional, Low, Hu Liang, additional, Alves, José Luís, additional, Maghrabi, Yazid, additional, Mammi, Marco, additional, Marji, Ala’, additional, Massimi, Luca, additional, Mavridis, Ioannis, additional, McLean, Aaron Lawson, additional, Lawson McLean, Anna C., additional, Meyer, Bernhard, additional, Mohme, Malte, additional, Branco, Pedro Moura, additional, Müther, Michael, additional, Musleh, Issam, additional, Nasiri, Danial, additional, Navarro, Ramon, additional, Omerhodzic, Ibrahim, additional, Oppong, Marvin Darkwah, additional, Paidakakos, Nikolaos A., additional, Pantera, Zoi, additional, Patel, Mohammed A., additional, Pawlowski, Mateusz, additional, Petridis, Athanasios, additional, Praeger, Adrian J., additional, Price, Stephen, additional, Ricklefs, Franz, additional, Rigante, Luigi, additional, Ringel, Florian, additional, Robe, Pierre A., additional, Rössler, Karl, additional, Sá-Marta, Eduarda, additional, Sanmillan, Jose L., additional, Scerrati, Alba, additional, Schneider, Matthias, additional, Schroeder, Henry W.S., additional, Schwake, Michael, additional, Shoaib, Mohamed, additional, Sirbu, Octavian Mihai, additional, Sistiaga, Iñigo L., additional, Skajster, Tomasz J., additional, Sliauzys, Albertas, additional, Sokotukhin, Vitaly, additional, Soleman, Jehuda, additional, Stoecklein, Veit M., additional, Molina, Eric Suero, additional, Świątnicki, Wojciech, additional, Syrmos, Νikolaos, additional, Taddei, Graziano, additional, Taher, Avin, additional, Tamarit, Martin, additional, Laan, Mark ter, additional, Theocharous, Theocharis, additional, Thijs, Dieter, additional, Trakolis, Leonidas, additional, Truffelli, Monica, additional, Weiss, Miriam, additional, Uhl, Eberhard, additional, Valentini, Laura Grazia, additional, Vanhauwaert, Dimitri, additional, Zebian, Bassel, additional, Zivkovic, Bojana, additional, and Zoli, Matteo, additional

Published
2024
Full Text
View/download PDF

17. ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM

Author

Happold, Caroline, Felsberg, Jörg, Clarke, Jennifer, Soffietti, Riccardo, Marosi, Christine, Krex, Dietmar, Ducray, François, Hau, Peter, Reijneveld, Jaap, Weyerbrock, Astrid, Wick, Antje, Reardon, David, Glas, Martin, Razis, Evangelia, Herrlinger, Ulrich, Tonn, Joerg-Christian, Carpentier, Antoine F, Lefranc, Florence, Rhun, Emilie Le, Verschuere, Tina, Golfinopoulos, Vassilis, Klein, Martin, Reifenberger, Guido, and Weller, Michael

Subjects
Neurosciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Abstract BACKGROUND Survival in glioblastoma patients is usually in the range of 12–15 months, and less than 5% of patients survive 5 years from diagnosis. Little is known about factors influencing long-term survival. METHODS A consortium generously funded by the Brain Tumor Funders’ Collaborative comprising more than 20 clinical sites in Europe, the US, and Australia registers patients with glioblastoma who survived for at least 5 years. The aim of the study is a better understanding of factors contributing to prolonged survival by assessment of (i) clinical features, (ii) molecular parameters, (iii) therapy and quality of life-related factors, and (iv) immunological parameters. The histopathological diagnosis of glioblastoma is centrally reviewed at study entry. Clinical characteristics including imaging data are collected at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium. Comprehensive molecular analyses are performed at the German Cancer Research Center (DKFZ), Germany. Immunological parameters are analyzed in Zurich, Switzerland. Alive patients are followed by neurocognitive assessments additionally. RESULTS At the cut-off of May 30, 2017, 182 patients have been registered by 17 sites; 107 patients are alive, more than half of which contribute to the neurocognitive assessments and patient-related outcome studies, as well as the immunological studies. First comprehensive results of disease characteristics with a cut-off of September 30, 2017, will be presented. CONCLUSIONS The collaborative effort of this consortium by comprehensive characterization of molecular parameters, immunological aspects, and individual clinical and therapy-related determinants will contribute to a better understanding of factors that modulate the course of this disease.

Published
2017

19. A vaccine targeting mutant IDH1 in newly diagnosed glioma

Author

Platten, Michael, Bunse, Lukas, Wick, Antje, Bunse, Theresa, Le Cornet, Lucian, Harting, Inga, Sahm, Felix, Sanghvi, Khwab, Tan, Chin Leng, Poschke, Isabel, Green, Edward, Justesen, Sune, Behrens, Geoffrey A., Breckwoldt, Michael O., Freitag, Angelika, Rother, Lisa-Marie, Schmitt, Anita, Schnell, Oliver, Hense, Jörg, Misch, Martin, Krex, Dietmar, Stevanovic, Stefan, Tabatabai, Ghazaleh, Steinbach, Joachim P., Bendszus, Martin, von Deimling, Andreas, Schmitt, Michael, and Wick, Wolfgang

Published
2021
Full Text
View/download PDF

21. Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

Author

Weller, Johannes, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Bähr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh, Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert, Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich, and Schäfer, Niklas

Published
2019
Full Text
View/download PDF

22. PATH-19. PROGNOSTIC FACTORS, RESPONSE TO TREATMENT, AND OUTCOME OF PATIENTS WITH ISOCITRATE DEHYDROGENASE (IDH)-MUTANT ASTROCYTOMA, CNS WHO GRADE 4

Author

Weller, Michael, primary, Felsberg, Jörg, additional, Hentschel, Bettina, additional, Gramatzki, Dorothee, additional, Kubon, Nadezhda, additional, Wolter, Marietta, additional, Roth, Patrick, additional, Krex, Dietmar, additional, Herrlinger, Ulrich, additional, Westphal, Manfred, additional, Tonn, Joerg-Christian, additional, Regli, Luca, additional, Maurage, Claude-Alain, additional, von Deimling, Andreas, additional, Pietsch, Torsten, additional, Rhun, Emilie Le, additional, and Reifenberger, Guido, additional

Published
2023
Full Text
View/download PDF

23. CTNI-65. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL

Author

Kebir, Sied, primary, Lazaridis, Lazaros, additional, Schmidt, Teresa, additional, Oster, Christoph, additional, Feldheim, Jonas, additional, Pierscianek, Daniela, additional, Proescholdt, Martin, additional, Hau, Peter, additional, Grosu, Anca-Ligia, additional, Krex, Dietmar, additional, Sure, Ulrich, additional, Scheffler, Björn, additional, Kleinschnitz, Christoph, additional, Pöttgen, Christoph, additional, Stuschke, Martin, additional, and Glas, Martin, additional

Published
2023
Full Text
View/download PDF

24. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial

Author

Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert, Weller, Johannes, Mack, Frederic, Tzaridis, Theophilos, Bähr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin, and Herrlinger, Ulrich

Published
2019
Full Text
View/download PDF

26. Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.

Author

Kebir, Seid, primary, Lazaridis, Lazaros, additional, Schmidt, Teresa, additional, Oster, Christoph, additional, Proescholdt, Martin, additional, Hau, Peter, additional, Grosu, Anca L., additional, Krex, Dietmar, additional, Sure, Ulrich, additional, Scheffler, Björn, additional, Kleinschnitz, Christoph, additional, Pöttgen, Christoph, additional, Stuschke, Martin, additional, and Glas, Martin, additional

Published
2023
Full Text
View/download PDF

28. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

Author

Schaub, Christina, Kebir, Sied, Junold, Nina, Hattingen, Elke, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Niessen, Michael, Mack, Frederic, Stuplich, Moritz, Tzaridis, Theophilos, Bähr, Oliver, Kortmann, Rolf-Dieter, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Braun, Christian, Hänel, Mathias, Sabel, Michael, Gerlach, Rüdiger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Herrlinger, Ulrich, and Glas, Martin

Published
2018
Full Text
View/download PDF

29. Movie 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

30. Movie 3 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Tables from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

32. Movie 1 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

33. Movie 4 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure Legends from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

35. Data from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

36. Abstract 1425: TTFields reduce sensitivity in glioblastoma is associated with the functional expression of the chloride intracellular channel 1 and with voltage dependent sodium channel

Author

Castiglione, Stefania, primary, Cannavale, Gaetano, additional, Cianci, Francesca, additional, Verduci, Ivan, additional, Biella, Chiara, additional, Mercurio, Chiara, additional, Pastorelli, Emanuela, additional, Lupi, Monica, additional, Paracchini, Laura, additional, Mannarino, Laura, additional, Krex, Dietmar, additional, Brandalise, Federico, additional, and Mazzanti, Michele, additional

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

40. Movie Legends from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 4 from Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

Author

Di Tacchio, Mariangela, primary, Macas, Jadranka, primary, Weissenberger, Jakob, primary, Sommer, Kathleen, primary, Bähr, Oliver, primary, Steinbach, Joachim P., primary, Senft, Christian, primary, Seifert, Volker, primary, Glas, Martin, primary, Herrlinger, Ulrich, primary, Krex, Dietmar, primary, Meinhardt, Matthias, primary, Weyerbrock, Astrid, primary, Timmer, Marco, primary, Goldbrunner, Roland, primary, Deckert, Martina, primary, Scheel, Andreas H., primary, Büttner, Reinhard, primary, Grauer, Oliver M., primary, Schittenhelm, Jens, primary, Tabatabai, Ghazaleh, primary, Harter, Patrick N., primary, Günther, Stefan, primary, Devraj, Kavi, primary, Plate, Karl H., primary, and Reiss, Yvonne, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 1 from TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study

Author

Juratli, Tareq A., primary, Stasik, Sebastian, primary, Zolal, Amir, primary, Schuster, Caroline, primary, Richter, Sven, primary, Daubner, Dirk, primary, Juratli, Mazen A., primary, Thowe, Rachel, primary, Hennig, Silke, primary, Makina, Meriem, primary, Meinhardt, Matthias, primary, Lautenschlaeger, Tim, primary, Schackert, Gabriele, primary, Krex, Dietmar, primary, and Thiede, Christian, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Data from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma

Author

Seidlitz, Annekatrin, primary, Beuthien-Baumann, Bettina, primary, Löck, Steffen, primary, Jentsch, Christina, primary, Platzek, Ivan, primary, Zöphel, Klaus, primary, Linge, Annett, primary, Kotzerke, Jörg, primary, Petr, Jan, primary, van den Hoff, Jörg, primary, Steinbach, Jörg, primary, Krex, Dietmar, primary, Schmitz-Schackert, Gabriele, primary, Falk, Monique, primary, Baumann, Michael, primary, and Krause, Mechthild, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data S1-2 from Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma

Author

Seidlitz, Annekatrin, primary, Beuthien-Baumann, Bettina, primary, Löck, Steffen, primary, Jentsch, Christina, primary, Platzek, Ivan, primary, Zöphel, Klaus, primary, Linge, Annett, primary, Kotzerke, Jörg, primary, Petr, Jan, primary, van den Hoff, Jörg, primary, Steinbach, Jörg, primary, Krex, Dietmar, primary, Schmitz-Schackert, Gabriele, primary, Falk, Monique, primary, Baumann, Michael, primary, and Krause, Mechthild, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results